AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15541832 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 990
Study 15541832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 11122885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 11122885 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9516764 — intervention group
Group type: EXPERIMENTAL
Intervention: Group instruction
Number of subjects: 152
Study 9516764 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 152
Study 9516764 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal instruction
Number of subjects: 152
Study 9516764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 8372768 — intervention group
Group type: EXPERIMENTAL
Intervention: MR arthrography with 40-50 ml of a 1:100 solution of gadopentetate dimeglumine in saline
Number of subjects: 37
Study 8372768 — intervention group
Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 37
Study 8372768 — intervention group
Group type: EXPERIMENTAL
Intervention: MR arthrography
Number of subjects: 37
Study 8372768 — intervention group
Group type: COMPARATOR
Intervention: Routine MR imaging
Number of subjects: 37
Study 3534730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 1 g IV every 8 hours for 5 days
Number of subjects: 60
Study 3534730 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole 800 mg sulfamethoxazole and 160 mg trimethoprim every 12 hours for 5 days
Number of subjects: 60
Study 30634046 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalization methods in biomedical informatics
Number of subjects: 0
Study 30634046 — intervention group
Group type: EXPERIMENTAL
Intervention: Design systems for eHealth applications
Number of subjects: 0
Study 30634046 — intervention group
Group type: EXPERIMENTAL
Intervention: Design systems that collect data for treatment personalization
Number of subjects: 0
Study 29424799 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine (2 doses)
Number of subjects: 148
Study 29424799 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 dose of measles-mumps-rubella and diphtheria-tetanus-acellular-pertussis vaccines)
Number of subjects: 148
Study 26666342 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin ≥ 0.20 ng/mL (N=104)
Number of subjects: 1781
Study 26666342 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin < 0.20 ng/mL
Number of subjects: 1781
Study 24462855 — intervention group
Group type: COMPARATOR
Intervention: Systemic methotrexate (MTX)
Number of subjects: 82
Study 24462855 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (MTX) combined with ultrasound-guided local injection of potassium chloride (KCl) or MTX
Number of subjects: 82
Study 24462855 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally injected potassium chloride (KCl)
Number of subjects: 82
Study 24462855 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally injected methotrexate (MTX)
Number of subjects: 82
Study 22626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Bup/Nal) for 12 weeks
Number of subjects: 152
Study 22626890 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Bup/Nal) for 2 weeks detoxification
Number of subjects: 152
Study 20642545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg (morning dosing)
Number of subjects: 48
Study 20642545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg (evening dosing)
Number of subjects: 48
Study 20642545 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of Vildagliptin 100 mg
Number of subjects: 48
Study 17715164 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 100-125 ppm carbon monoxide (CO) for 2 hours per day over 4 consecutive days.
Number of subjects: 20
Study 17715164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract).
Number of subjects: 20
Study 16248379 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy
Number of subjects: 14
Study 16248379 — intervention group
Group type: COMPARATOR
Intervention: AMI
Number of subjects: 14
Study 12065335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI), 300 mg bid
Number of subjects: 520
Study 12065335 — intervention group
Group type: COMPARATOR
Intervention: Oral quinolone antibiotics (primarily ciprofloxacin)
Number of subjects: 520
Study 12065335 — intervention group
Group type: COMPARATOR
Intervention: TSI therapy
Number of subjects: 520
Study 12065335 — intervention group
Group type: COMPARATOR
Intervention: S maltophilia culture frequency
Number of subjects: 520
Study 9537270 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3 doses at 2, 3, and 4 months of age)
Number of subjects: 171
Study 9537270 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatitis B, OPV, and DPT without HbOC)
Number of subjects: 171
Study 7616334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 125
Study 7616334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus naltrexone
Number of subjects: 125
Study 2523611 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex), 3.6 mg sc/28 d
Number of subjects: 0
Study 2523611 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES), 1 mg tid
Number of subjects: 0
Study 904400 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy evaluation using Rinkle and Lee techniques for inhalent and food allergies.
Number of subjects: 14
Study 904400 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge food tests administered to patients.
Number of subjects: 14
Study 31937553 — intervention group
Group type: EXPERIMENTAL
Intervention: Active respiratory muscle training (RMT) performed twice daily for 6 weeks
Number of subjects: 62
Study 31937553 — intervention group
Group type: COMPARATOR
Intervention: Sham respiratory muscle training
Number of subjects: 62
Study 31937553 — intervention group
Group type: EXPERIMENTAL
Intervention: Active respiratory muscle training (RMT)
Number of subjects: 62
Study 29982701 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone) at adequate doses
Number of subjects: 6221
Study 28294136 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (10 mg)
Number of subjects: 30
Study 28294136 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg)
Number of subjects: 30
Study 28294136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 25807878 — intervention group
Group type: EXPERIMENTAL
Intervention: Image Integration Module (IIM, CartoUnivu™ Module)
Number of subjects: 60
Study 25807878 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3D mapping system (Carto® 3 System)
Number of subjects: 60
Study 23865528 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based weight management program
Number of subjects: 349
Study 21403042 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering Patients in Care (EPIC) intervention
Number of subjects: 87
Study 21403042 — intervention group
Group type: COMPARATOR
Intervention: Group education sessions with a DM educator and dietician
Number of subjects: 87
Study 19494100 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety education with provision of safety equipment
Number of subjects: 0
Study 16884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct associations
Number of subjects: 63
Study 16884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Related associations
Number of subjects: 63
Study 16884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong associations (rated > 5)
Number of subjects: 63
Study 16884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated associations
Number of subjects: 63
Study 15327447 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving method
Number of subjects: 300
Study 15327447 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving method
Number of subjects: 300
Study 15327447 — intervention group
Group type: COMPARATOR
Intervention: Double-outer gloves
Number of subjects: 300
Study 11249051 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiotepa (600 mg/m2) + melphalan (160 mg/m2) with hemopoietic support
Number of subjects: 48
Study 11249051 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiotepa and melphalan
Number of subjects: 48
Study 9623012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study 7940765 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA
Number of subjects: 59
Study 7940765 — intervention group
Group type: COMPARATOR
Intervention: AzaP
Number of subjects: 59
Study 3369327 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral self-help booklets
Number of subjects: 304
Study 3369327 — intervention group
Group type: COMPARATOR
Intervention: Factual information pamphlet (Control)
Number of subjects: 304
Study 3369327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 304
Study 29329169 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 178
Study 29329169 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 178
Study 26173792 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 41
Study 26173792 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 41
Study 26239087 — intervention group
Group type: EXPERIMENTAL
Intervention: bendamustine-rituximab (B-R)
Number of subjects: 173
Study 26239087 — intervention group
Group type: COMPARATOR
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Number of subjects: 173
Study 26239087 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment Bcl-2/IgH status
Number of subjects: 173
Study 22850489 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) combined with physical therapy modalities and joint mobilization
Number of subjects: 30
Study 22850489 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy modalities and passive joint mobilization of the shoulder (non-WBC group)
Number of subjects: 30
Study 21118164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine added to standard therapy
Number of subjects: 78
Study 21118164 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of SA and CHF
Number of subjects: 78
Study 18708685 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 18
Study 18708685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16847937 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate only (P) filter
Number of subjects: 64
Study 16847937 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate/organic vapor (POV) filter
Number of subjects: 64
Study 16847937 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate/organic vapor/formaldehyde (POVF) filter
Number of subjects: 64
Study 12920843 — intervention group
Group type: EXPERIMENTAL
Intervention: AT group
Number of subjects: 24
Study 12920843 — intervention group
Group type: COMPARATOR
Intervention: non AT group
Number of subjects: 24
Study 12920843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 10960460 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiviral therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily, amantadine 200 mg daily) for 12 months
Number of subjects: 60
Study 10960460 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily) for 12 months
Number of subjects: 60
Study 10960460 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiviral therapy
Number of subjects: 60
Study 10960460 — intervention group
Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 60
Study 8870441 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 50
Study 8870441 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 2000817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard-modified formula
Number of subjects: 36
Study 2000817 — intervention group
Group type: COMPARATOR
Intervention: Unmodified formula
Number of subjects: 36
Study 2000817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 6342543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment together with intrathecal equine antitetanus serum
Number of subjects: 161
Study 6342543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus serum with systemic betamethasone
Number of subjects: 161
Study 6342543 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 161
Study 6342543 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral intramuscular diazepam as a sedative
Number of subjects: 161
Study 6342543 — intervention group
Group type: COMPARATOR
Intervention: Paraldehyde as a sedative
Number of subjects: 161
Study 31350853 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm from randomized controlled trials (RCTs)
Number of subjects: 0
Study 31350853 — intervention group
Group type: COMPARATOR
Intervention: EC-derived control arm
Number of subjects: 0
Study 30924791 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry-based activity monitor (MyWellnessKey) and associated Web platform (MyWellnessCloud) plus usual practice (n=88)
Number of subjects: 156
Study 30924791 — intervention group
Group type: COMPARATOR
Intervention: Usual practice only (n=68)
Number of subjects: 156
Study 30429941 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled HIV/HCV testing
Number of subjects: 478
Study 30429941 — intervention group
Group type: COMPARATOR
Intervention: HIV testing alone
Number of subjects: 478
Study 26370827 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Care (CGC)
Number of subjects: 397
Study 26370827 — intervention group
Group type: COMPARATOR
Intervention: Conventional Orthopaedic Care (OC)
Number of subjects: 397
Study 25169631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg, tid
Number of subjects: 64
Study 25169631 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (low‐flow oxygen, low‐salt diet therapy, cardiac therapy)
Number of subjects: 64
Study 23118406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopneumatic device
Number of subjects: 280
Study 23118406 — intervention group
Group type: COMPARATOR
Intervention: Ice with static compression
Number of subjects: 280
Study 20709385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences containing homophones
Number of subjects: 0
Study 20709385 — intervention group
Group type: COMPARATOR
Intervention: Sentences without homophones
Number of subjects: 0
Study 17409306 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) + usual care (n = 24)
Number of subjects: 49
Study 17409306 — intervention group
Group type: COMPARATOR
Intervention: Usual care control only (n = 25)
Number of subjects: 49
Study 16623032 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of happiness (57.3%)
Number of subjects: 438
Study 16623032 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrovert personality, stable personality, high family income, improved marital relationship
Number of subjects: 438
Study 16820805 — intervention group
Group type: EXPERIMENTAL
Intervention: HydraBrush Oral Health System (OHS)
Number of subjects: 100
Study 16820805 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Elite 7800 (SE)
Number of subjects: 100
Study 10937603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75
Study 10937603 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (fluoxetine or bupropion)
Number of subjects: 75
Study 8880051 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms zacopride
Number of subjects: 3
Study 8880051 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms zacopride
Number of subjects: 3
Study 8880051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 1520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiped with dry cloth alone
Number of subjects: 141
Study 1520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Put into a plastic bag immediately after birth
Number of subjects: 141
Study 1520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiped with dry cloth and then inserted into a plastic bag
Number of subjects: 141
Study 6840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine
Number of subjects: 16
Study 6840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 16
Study 6840904 — intervention group
Group type: COMPARATOR
Intervention: Drug-free period
Number of subjects: 16
Study 30700278 — intervention group
Group type: EXPERIMENTAL
Intervention: Song of Life (SOL) music therapy
Number of subjects: 104
Study 30700278 — intervention group
Group type: COMPARATOR
Intervention: Relaxation exercises (control group)
Number of subjects: 104
Study 30295329 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing-assisted interview
Number of subjects: 84
Study 30295329 — intervention group
Group type: COMPARATOR
Intervention: Verbal cued-recall interview
Number of subjects: 84
Study 27155189 — intervention group
Group type: COMPARATOR
Intervention: R10 (control regimen)
Number of subjects: 300
Study 27155189 — intervention group
Group type: EXPERIMENTAL
Intervention: R15 (Study Regimen 1)
Number of subjects: 300
Study 27155189 — intervention group
Group type: EXPERIMENTAL
Intervention: R20 (Study Regimen 2)
Number of subjects: 300
Study 23789615 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD and brochure
Number of subjects: 0
Study 23789615 — intervention group
Group type: COMPARATOR
Intervention: Brochures only
Number of subjects: 0
Study 22453248 — intervention group
Group type: EXPERIMENTAL
Intervention: oral glycerol = sports drink, water, and glycerol
Number of subjects: 9
Study 22453248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV = half as normal saline, half of sports drink, and water
Number of subjects: 9
Study 22453248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV with oral glycerol = half as normal saline, half as sports drink, water, and glycerol
Number of subjects: 9
Study 22453248 — intervention group
Group type: COMPARATOR
Intervention: oral = sports drink and water
Number of subjects: 9
Study 20400004 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO(4)) infusion
Number of subjects: 60
Study 20400004 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group C)
Number of subjects: 60
Study 17511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cure adhesive
Number of subjects: 60
Study 17511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sandblasting with tribochemical silica coating
Number of subjects: 60
Study 17511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 microm aluminum oxide
Number of subjects: 60
Study 17511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating
Number of subjects: 60
Study 17511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sandblasting and tribochemical silica coating
Number of subjects: 60
Study 16317826 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 16317826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12162381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO2) - 40 sessions over 2 months, 1 hour exposure to 100% oxygen at 1.75 ATA
Number of subjects: 75
Study 12162381 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment - 40 sessions over 2 months, 1 hour exposure to air at 1.3 ATA
Number of subjects: 75
Study 12162381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HBO2 and sham)
Number of subjects: 75
Study 10408720 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0
Study 10408720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management strategies (empathy, emotional support)
Number of subjects: 0
Study 7675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodybuilding program
Number of subjects: 45
Study 7675585 — intervention group
Group type: COMPARATOR
Intervention: Aerobics
Number of subjects: 45
Study 7675585 — intervention group
Group type: COMPARATOR
Intervention: Circuit training
Number of subjects: 45
Study 30306805 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic techniques (20 sessions, twice weekly)
Number of subjects: 103
Study 30306805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 103
Study 27220348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (120 mg subcutaneously every 2 or 4 weeks)
Number of subjects: 2262
Study 27220348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2262
Study 25218783 — intervention group
Group type: EXPERIMENTAL
Intervention: miravirsen
Number of subjects: 36
Study 25218783 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 22570325 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual imagery intervention
Number of subjects: 101
Study 22570325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 19546818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m2 in 20 to 30 minutes) + Cisplatin (75 mg/m2 on day 2)
Number of subjects: 249
Study 19546818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2)
Number of subjects: 249
Study 19546818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2) in patients with squamous carcinoma
Number of subjects: 249
Study 19546818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 249